Research news

CT-P6, a biosimilar of trastuzumab, has similar efficacy, pharmacokinetics, and safety to its reference drug when used in neoadjuvant treatment of HER2-positive early-stage breast cancer, say researchers.

Olaparib delays disease progression by nearly 3 months compared with standard chemotherapy in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer and a germline BRCA mutation, results from the phase III OlympiAD trial show.

In this report from the 2017 annual meeting of the American Society of Clinical Oncology we focus on three studies that evaluated interventions to help patients and their families manage the psychological toll of cancer through the disease continuum.

Multifraction radiotherapy is unnecessary for some patients with spinal cord compression symptoms in late-stage cancer, suggest SCORAD III study findings reported at the 2017 annual meeting of the American Society of Clinical Oncology in Chicago, Illinois, USA.